Kakei M, Nakazaki M, Kamisaki T, Nagayama I, Fukamachi Y, Tanaka H. Inhibition of the ATP-sensitive potassium channel by class I antiarrhythmic agent, cibenzoline, in rat pancreatic beta-cells. Br J Pharmacol. 1993;109:1226–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, et al. Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release. Am J Physiol. 1993;265:C337–42.

Article  CAS  PubMed  Google Scholar 

Kim SY, Benowitz NL. Poisoning due to class IA antiarrhythmic drugs Quinidine, procainamide and disopyramide. Drug Saf. 1990;5(6):393–420.

Article  CAS  PubMed  Google Scholar 

Horie M, Hayashi S, Yuzuki Y, Sasayama S. Comparative studies of ATP sensitive potassium channels in heart and pancreatic beta cells using Vaughan-Williams class Ia antiarrhythmics. Cardiovasc Res. 1992;26:1087–94.

Article  CAS  PubMed  Google Scholar 

Massarella JW, Khoo KC, Szuna AJ, Sandor DA, Morganroth J, Aogaichi K. Pharmacokinetics of cibenzoline after single and repetitive dosing in healthy volunteers. J Clin Pharmacol. 1986;26:125–30.

Article  CAS  PubMed  Google Scholar 

Haraguchi T, Yamazaki Y, Kuwata H, Usui R, Hamamoto Y, Seino Y, et al. Glucagon stimulation test and insulin secretory capacity in the clinical assessment of incretin-based therapy for diabetes. Diabetes. 2024;73:2078–83.

Article  CAS  PubMed  Google Scholar 

Fujita Y, Kozawa J, Iwahashi H, Yoneda S, Uno S, Yoshikawa A, et al. Increment of serum C-peptide measured by glucagon test closely correlates with human relative beta-cell area. Endocr J. 2015;62:329–37.

Article  CAS  PubMed  Google Scholar 

Hilleman DE, Mohiuddin SM, Ahmed IS, Dahl JM. Cibenzoline-induced hypoglycemia. Drug Intell Clin Pharm. 1987;21:38–40.

CAS  PubMed  Google Scholar 

Gachot BA, Bezier M, Cherrier JF, Daubeze J. Cibenzoline and hypoglycaemia. Lancet. 1988;2:280.

Article  CAS  PubMed  Google Scholar 

Jeandel C, Preiss MA, Pierson H, Penin F, Cuny G, Bannwarth B, et al. Hypoglycaemia induced by cibenzoline. Lancet. 1988;1:1232–3.

Article  CAS  PubMed  Google Scholar 

Similowski T, Straus C, Attali V, Girard F, Philippe F, Deray G, et al. Neuromuscular blockade with acute respiratory failure in a patient receiving cibenzoline. Thorax. 1997;52:582–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ogimoto A, Hamada M, Saeki H, Hiasa G, Ohtsuka T, Hashida H, et al. Hypoglycemic syncope induced by a combination of cibenzoline and angiotensin converting enzyme inhibitor. Jpn Heart J. 2001;42:255–9.

Article  CAS  PubMed  Google Scholar 

Takahashi M, Echizen H, Takahashi K, Shimada S, Aoyama N, Izumi T. Extremely prolonged elimination of cibenzoline at toxic plasma concentrations in patients with renal impairments. Ther Drug Monit. 2002;24:492–6.

Article  CAS  PubMed  Google Scholar 

Majima T, Takagi C, Koike Y, Shigemoto M, Yamada T, Akagi T. Cibenzoline-succinate-induced hypoglycemia. Nippon Naika Gakkai Zasshi. 2004;93:2197–200.

Article  PubMed  Google Scholar 

Vandecandelaere P, Verbanck J, Matthys K, de Hoon J, Verbesselt R. Symptomatic hypoglycemia in a patient with chronic hemodialysis. Acta Clin Belg. 2006;61:249–51.

Article  CAS  PubMed  Google Scholar 

Hirata Y, Kamei S, Tatsumi F, Shimoda M, Tanabe A, Sanada J, et al. Hypoglycemic coma induced by the use of succinic acid cibenzoline in frail late-stage elderly subjects. Intern Med. 2017;56:1527–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakagawa Y, Ishizaki M, Kozono A, Hanada K, Higashi T, Ueyama H. A case of myasthenia-like symptoms induced by cibenzoline overdosage. Rinsho Shinkeigaku. 2018;58:41–4.

Article  PubMed  Google Scholar 

Iha T, Watanabe A, Saeki M, Itoh A, Kashiwabara Y, Fujiwara A, et al. Combined sepsis- and renal dysfunction-induced hypoglycaemia in an older patient taking cibenzoline. Clin Case Rep. 2024;12:e8816.

Article  PubMed  PubMed Central  Google Scholar 

Ohkura T, Shiochi H, Fujioka Y, Sumi K, Yamamoto N, Matsuzawa K, et al. 20/ (fasting C-peptide × fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol. 2013;12:21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227–36.

Article  CAS  PubMed  Google Scholar 

Carnovale C, Gringeri M, Battini V, Mosini G, Invernizzi E, Mazhar F, et al. Beta-blocker-associated hypoglycaemia: New insights from a real-world pharmacovigilance study. Br J Clin Pharmacol. 2021;87:3320–31.

Article  CAS  PubMed  Google Scholar 

Hakusui H, Fujimaki M. Pharmacokinetics of carvedilol in hypertensive patients with renal failure. Drugs. 1988;36:144–7.

Article  Google Scholar 

Sakurai K, Katayama E, Motegi H. A case of severe hypoglycemia induced by the combination use of a DPP-4 inhibitor and antiarrhythmic agent. J Japan Diab Soc. 2015;58:323–8.

Google Scholar 

Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007;30:1862–4.

Article  CAS  PubMed  Google Scholar